• Elyse O Kharbanda, Gabriela Vazquez-Benitez, Heather Lipkind, Allison L Naleway, Nicola P Klein, T Craig Cheetham, Simon J Hambidge, Claudia Vellozzi, and James D Nordin.
• HealthPartners Institute for Education and Research, Minneapolis, MN, United States. Electronic address: Elyse.o.kharbanda@healthpartners.com.
• Prev Med. 2014 Oct 1; 67: 316-9.

ObjectiveIn response to widespread pertussis outbreaks and infant deaths, in 2010, the California Department of Health (CDPH) and in 2011 the Advisory Committee on Immunization Practices (ACIP) advised that the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine be administered during pregnancy. The goals of this study were to describe Tdap coverage among pregnant women following these recommendations.MethodsIn this observational cohort study, we utilized electronic medical record and claims data from seven Vaccine Safety Datalink sites to identify pregnancies and Tdap administrations. All Tdap doses were classified as pre-pregnancy, during pregnancy or post-pregnancy/postpartum. For pregnancies ending in a live birth, we evaluated factors associated with Tdap vaccination.ResultsAmong 289,141 live births at the California VSD sites, receipt of Tdap during pregnancy increased substantially in the years 2010, 2011, and 2012, when coverage was 15.9, 30.0 and 19.5%, respectively. Among 82,398 women with live births at the Oregon, Washington, Colorado, Wisconsin and Minnesota VSD sites, receipt of Tdap during pregnancy first increased in 2012, at 16.0%. Women receiving early prenatal care and other vaccine(s) during pregnancy had higher Tdap coverage.ConclusionWe observed substantial increases in Tdap coverage during pregnancy following CDPH and ACIP recommendations.Copyright © 2014 Elsevier Inc. All rights reserved.

19 keywords...

hide…